S.A. blood center enters a new realm in the field of regenerative medicine | Investor Stemcell

“The Blood & Tissue Center generated $140.1 million in revenue last year, according to its annual report.”

and,

 

GenCure is “filling a niche for a very high-growth industry and at the same time fulfilling another mission — treating patients,” Badylak said in an interview. “The field has grown so fast that the need for source material has exceeded the supply.”

GenCure currently only processes human tissue, but Fisk said it is exploring the possibility of processing pig tissue for transplantation in humans.

BioMed SA, which promotes San Antonio’s heath care and bioscience industries, earlier this year created a regenerative medicine committee to encourage collaboration among local officials working in the field. Fisk is a committee member.

“Regenerative medicine is a very dynamic, emerging field of medicine,” said Ann Stevens, BioMed SA’s president. “The Blood & Tissue Center is positioned to be an important player in that arena.”

More:

South Texas Blood & Tissue Center is jumping into the field of regenerative medicine.

Through a new subsidiary called GenCure, the nonprofit group is focusing on providing tissue and cells for use in the treatment of patients and for clinical research.

GenCure expands the Blood & Tissue Center’s life-saving mission to include assisting in the replacement of missing or injured muscle tissue and aiding in the treatment of various diseases.

“We are uniquely different. Other blood centers do not have this diversification,” said Mary Beth Fisk, the Blood & Tissue Center’s interim president and chief operating officer.

GenCure actually was formed last year to capitalize on the regenerative-medicine aspects of the center’s Texas Cord Blood Bank, its Marrow Donor Program of South and Central Texas, and its Tissue Services unit, which collects donated human tissue. GenCure, also a nonprofit, employs about 75 people.

via S.A. blood center enters a new realm in the field of regenerative medicine | Investor Stemcell.